Advice
Following a full submission
busulfan for intravenous infusion (Busilvex®) is accepted for use within NHS Scotland as part of a combination regimen for conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in paediatric and adult patients. The intravenous preparation offers advantages to patients over the oral formulation in terms of convenience of administration and predictability of blood levels.
In adults it should be followed by cyclophosphamide (BuCy2) and in children it should be followed by cyclophosphamide (BuCy4) or by melphalan (BuMel).
Download detailed advice43KB (PDF)
Medicine details
- Medicine name:
- busulfan, 6mg/ml, intravenous (Busilvex)
- SMC ID:
- 337/06
- Indication:
- Conditioning treatment prior to conventional haematopoietic progenitor cell transplantation
- Pharmaceutical company
- Pierre Fabre Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 15 January 2007